https://www.businesswire.com/news/home/20230705871911/en/OSE-Immunotherapeutics-Announces-for-Lusvertikimab-its-Anti-IL-7-Receptor-Antagonist
OSE Immunotherapeutics Announces for Lusvertikimab, its Anti-IL-7 Receptor Antagonist:
OSE Immunotherapeutics Announces for Lusvertikimab, its Anti-IL-7 Receptor Antagonist
il 7 receptoroseimmunotherapeuticsannounces